News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,315 Results
Type
Article (54231)
Company Profile (267)
Press Release (652817)
Section
Business (199808)
Career Advice (3111)
Deals (36563)
Drug Delivery (115)
Drug Development (83712)
Employer Resources (172)
FDA (16960)
Job Trends (16026)
News (347107)
Policy (34653)
Tag
Academia (2898)
Alliances (50011)
Alzheimer's disease (1379)
Approvals (16896)
Artificial intelligence (183)
Bankruptcy (357)
Best Places to Work (12413)
Biotechnology (152)
Breast cancer (210)
Cancer (1566)
Cardiovascular disease (136)
Career advice (2611)
CAR-T (118)
Cell therapy (340)
Clinical research (66915)
Collaboration (585)
Compensation (303)
COVID-19 (2760)
C-suite (140)
Data (1489)
Diabetes (202)
Diagnostics (6642)
Earnings (76327)
Employer resources (152)
Events (112159)
Executive appointments (480)
FDA (17742)
Funding (516)
Gene therapy (239)
GLP-1 (720)
Government (4768)
Healthcare (20517)
Infectious disease (2865)
Inflammatory bowel disease (126)
Interviews (612)
IPO (16851)
Job creations (4052)
Job search strategy (2150)
Layoffs (482)
Legal (8263)
Lung cancer (239)
Manufacturing (235)
Medical device (14187)
Medtech (14192)
Mergers & acquisitions (19961)
Metabolic disorders (552)
Neuroscience (1767)
NextGen: Class of 2025 (7236)
Non-profit (4997)
Northern California (1887)
Obesity (313)
Opinion (245)
Patents (137)
People (59378)
Phase I (20677)
Phase II (29365)
Phase III (22179)
Pipeline (621)
Postmarket research (2777)
Preclinical (8745)
Radiopharmaceuticals (258)
Rare diseases (309)
Real estate (6059)
Regulatory (23290)
Research institute (2595)
Resumes & cover letters (493)
Southern California (1626)
Startups (3652)
United States (16964)
Vaccines (633)
Weight loss (242)
Date
Today (195)
Last 7 days (949)
Last 30 days (2237)
Last 365 days (36939)
2025 (1351)
2024 (37229)
2023 (42302)
2022 (53642)
2021 (58369)
2020 (57232)
2019 (50705)
2018 (38448)
2017 (34819)
2016 (34198)
2015 (39649)
2014 (31535)
2013 (26493)
2012 (28144)
2011 (28703)
2010 (26132)
Location
Africa (958)
Arizona (174)
Asia (43157)
Australia (7680)
California (4248)
Canada (1538)
China (363)
Colorado (196)
Connecticut (214)
Europe (96693)
Florida (600)
Georgia (150)
Illinois (444)
Indiana (251)
Maryland (709)
Massachusetts (3386)
Michigan (201)
Minnesota (331)
New Jersey (1208)
New York (1199)
North Carolina (852)
Northern California (1887)
Ohio (157)
Pennsylvania (999)
South America (1326)
Southern California (1626)
Texas (615)
Utah (126)
Washington State (441)
707,315 Results for "moberg pharma ab formerly known as moberg derma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Cipher Pharmaceuticals Partner Moberg Pharma AB Reports Topline Data in MOB-015 Phase 3 Study
December 10, 2024
·
7 min read
Moberg Pharma has secured exercise of warrants and entered into a top guarantee free of charge - June 11, 2024
Moberg Pharma AB has received subscription intentions, subscription commitments and top guarantee commitments totaling approximately SEK 113.5 million, related to the warrants of series 2023:1, from a few external professional investors and the Company’s largest shareholder, Östersjöstiftelsen.
June 11, 2024
·
7 min read
Drug Development
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
September 13, 2024
·
6 min read
Moberg Pharma receives SEK 336 million through TO 2 and directed issue to top guarantors - subscription rate in TO 2 of 98%
Moberg Pharma announces that 17,776,856 warrants of series 2023:1 were exercised for subscription of in total 17,776,856 ordinary shares for approximately SEK 320 million, corresponding to a subscription rate of approximately 98%.
June 24, 2024
·
6 min read
Drug Development
Moberg Pharma has completed enrollment to the Phase 3 study for MOB-015 in North America
Moberg Pharma AB has completed the recruitment of 384 patients with onychomycosis for the ongoing MOB-015 phase 3 study in North America.
October 6, 2023
·
3 min read
Drug Development
MOB-015 is recommended for approval in EU: Moberg Pharma
Moberg Pharma AB hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults.
June 28, 2023
·
8 min read
MOB-015 is launched in Sweden under the brand name Terclara- pharmacies report major demand for the new medication
Moberg Pharma ABs marker partner in Sweden - Allderma AB, a company which specialises in the sale of over-the-counter pharmaceuticals - has now launched sales of MOB-015 under the Terclara® brand.
February 7, 2024
·
4 min read
Moberg Pharma and Padagis sign agreement for MOB-015 in Israel
Moberg Pharma AB has signed a distribution agreement with Padagis Israel Agencies Ltd. for MOB-015 in Israel and the Palestinian territories.
August 4, 2022
·
2 min read
Business
Moberg Pharma enters into collaboration with Allderma for launch in Scandinavia
Moberg Pharma AB has entered into a collaboration with Allderma AB for the launch of MOB-015 in Sweden, Norway and Denmark.
November 8, 2021
·
2 min read
Drug Development
Cipher Pharmaceuticals Announces Partner, Moberg Pharma’s Regulatory Submission to FDA for North American Phase 3 Study
Cipher Pharmaceuticals Inc. (TSX: CPH) (“Cipher” or “the Company”) today announced that the Company’s partner, Moberg Pharma AB, (“Moberg Pharma”) has submitted a regulatory filing for the next clinical Phase 3 study for MOB-015 (nail fungus treatment) to the U.S. Food and Drug Administration (“FDA”).
March 22, 2022
·
8 min read
1 of 70,732
Next
